Table 2.
Parameters | Multivariate analysis | ||||
---|---|---|---|---|---|
B | Wald | p | Exp(B) | 95%CI for Exp(B) | |
Sex | −0.584 | 0.774 | 0.379 | 0.558 | 0.152–2.049 |
Age at outpatient | 0.028 | 0.451 | 0.502 | 1.029 | 0.947–1.118 |
Currently employed | −0.744 | 2.004 | 0.157 | 0.475 | 0.170–1.331 |
Disease duration | 0.029 | 0.369 | 0.544 | 1.029 | 0.938–1.130 |
NSAIDs | 1.258 | 5.757 | 0.016 | 3.517 | 1.259–9.827 |
csDMARDs | −0.293 | 0.203 | 0.652 | 0.746 | 0.209–2.663 |
TNF-i | 0.984 | 2.317 | 0.128 | 2.675 | 0.754–9.492 |
BASFI | −0.002 | 0.038 | 0.845 | 0.998 | 0.981–1.016 |
SF-12 PCS | −0.014 | 0.261 | 0.609 | 0.986 | 0.935–1.040 |
ASQoL | 0.021 | 0.117 | 0.733 | 1.021 | 0.906–1.151 |
ESR | 0.010 | 0.240 | 0.624 | 1.010 | 0.972–1.049 |
CRP | 0.024 | 1.373 | 0.241 | 1.024 | 0.984–1.067 |
HGB | −0.016 | 0.557 | 0.455 | 0.984 | 0.944–1.026 |
NSAIDs, nonsteroidal anti-inflammatory drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; TNF-i, tumor necrosis factor-α inhibitor; BASFI, Bath Ankylosing Spondylitis Functional Index; SF-12 PCS, Short Form-12 Physical Component Summary; ASQoL, Ankylosing Spondylitis Quality of Life; ESR, Erythrocyte Sedimentation Rate; CRP, C-reactive protein; HGB, hemoglobin